This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Novo Nordisk A/s. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Lars Holm Damgaard: Innovator in Medical Therapy
Introduction
Lars Holm Damgaard is a notable inventor based in Herlev, Denmark. He has made significant contributions to the field of medical therapy, particularly in the area of weight management and liver health. With a total of 2 patents, his work has garnered attention in the medical community.
Latest Patents
Lars's latest patents include innovative uses of semaglutide, a GLP-1 receptor agonist. The first patent focuses on semaglutide for use in weight management, highlighting its potential benefits in helping individuals achieve healthier weight levels. The second patent addresses the use of semaglutide in the treatment of non-alcoholic steatohepatitis, a condition that affects liver health.
Career Highlights
Lars Holm Damgaard is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. His work at Novo Nordisk has allowed him to contribute to groundbreaking advancements in medical therapies.
Collaborations
Throughout his career, Lars has collaborated with esteemed colleagues, including Soeren Oestergaard Hardt-Lindberg and Thomas Kruse Hansen. These collaborations have further enriched his research and development efforts.
Conclusion
Lars Holm Damgaard's innovative work in medical therapy, particularly with semaglutide, showcases his commitment to improving health outcomes. His contributions are paving the way for advancements in the treatment of weight management and liver diseases.